Radiopharm CMO reports large option holdings

Radiopharm Theranostics Ltd executive Dimitris Voliotis, the Chief Medical Officer, reported his initial holdings of stock options in a Form 3.

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd executive Dimitris Voliotis, the Chief Medical Officer, reported his initial holdings of stock options in a Form 3. These options give him the right to buy Ordinary Shares at an exercise price of $0.025 per share.

The filing shows three option positions over Ordinary Shares: one over 7,657,334 shares with an exercise date of July 1, 2028, and two over 7,657,333 shares each with exercise dates of July 1, 2027 and July 1, 2026. All three option positions are scheduled to expire on July 1, 2030 and are held directly. The filing does not report any purchases or sales, only these existing derivative holdings.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Voliotis Dimitris

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--

Holdings After Transaction: Option (right to buy) — 22,972,000 contracts (Direct)

Key Figures

Option exercise price: $0.025 per share Underlying shares (grant 1): 7,657,334 shares Underlying shares (grant 2): 7,657,333 shares +3 more

6 metrics

Option exercise price $0.025 per share Exercise price for reported options over Ordinary Shares

Underlying shares (grant 1) 7,657,334 shares Underlying Ordinary Shares for one option position

Underlying shares (grant 2) 7,657,333 shares Underlying Ordinary Shares for second option position

Underlying shares (grant 3) 7,657,333 shares Underlying Ordinary Shares for third option position

Exercise dates July 1, 2026 / 2027 / 2028 Stated exercise dates for the three option positions

Expiration date July 1, 2030 Common expiration date for all reported options

Key Terms

Form 3, Option (right to buy, Ordinary Shares

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): initial statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Option (right to buy financial

"security_title: "Option (right to buy)" describing derivative holdings"

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares" linked to the options"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What does the Radiopharm Theranostics (RADX) Form 3 for Dimitris Voliotis show?

The Form 3 reports Chief Medical Officer Dimitris Voliotis’s existing holdings of stock options. These options give him rights over multiple blocks of Ordinary Shares at a low exercise price, but the filing shows no purchases or sales, only current derivative positions.

How many Radiopharm Theranostics (RADX) shares are covered by Voliotis’s options?

The filing lists three option positions. One covers 7,657,334 Ordinary Shares, and two cover 7,657,333 Ordinary Shares each. These figures represent the underlying shares tied to his options, not shares currently owned outright or recently traded in the market.

What is the exercise price of Dimitris Voliotis’s options in Radiopharm Theranostics (RADX)?

All listed options have an exercise price of $0.025 per share. This means he can acquire the underlying Ordinary Shares at $0.025 if he exercises the options, subject to the specified exercise dates and the common July 1, 2030 expiration date.

When do the Radiopharm Theranostics (RADX) options held by Voliotis become exercisable and when do they expire?

The options show exercise dates of July 1, 2026, July 1, 2027, and July 1, 2028. Despite different exercise dates, all three option positions share the same expiration date of July 1, 2030, after which they can no longer be exercised for Ordinary Shares.

Does the Radiopharm Theranostics (RADX) Form 3 indicate any recent insider buying or selling by Dimitris Voliotis?

No, the Form 3 does not show any recent purchases or sales. It records existing holdings of options described as “Option (right to buy)” with unknown transaction codes, reflecting derivative positions rather than new open-market or private share transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 09:08 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Voliotis Dimitris

(Last) (First) (Middle)

SUITE 1 LEVEL 3, 62 LYGON STREET

(Street)

CARLTON SOUTH, VICTORIA NEW YORK 3053

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Radiopharm Theranostics Ltd [ RADX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	07/01/2026	07/01/2030	Ordinary Shares	7,657,333	$0.025	D
Option (right to buy)	07/01/2027	07/01/2030	Ordinary Shares	7,657,333	$0.025	D
Option (right to buy)	07/01/2028	07/01/2030	Ordinary Shares	7,657,334	$0.025	D

Explanation of Responses:

Remarks:

1. All exercise prices are in Australian dollars. 2. There are no non-derivative securities beneficially owned.

	/s/ Dimitris Voliotis	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)